The Global mRNA Treatment Market Size is estimated to be valued at 8.03 billion in 2024 and is predicted to reach 1.05 billion by the year 2031 at a 9.0% CAGR during 2028-2031.
Key Industry Insights & Findings from the Report:
- The increasing existance of chronic diseases such as cancer, viral infections, and genetic disorders is driving the demand for mRNA treatments.
- The development of advanced lipid nanoparticle formulations for in vivo systemic delivery of mRNA is fueling the mRNA treatment market.
- North America dominated the market and accounted for a global revenue share in 2023.
- The key challenges for the mRNA treatment market are process of vaccine and drug development is time-consuming and requires extensive clinical trials to ensure safety and efficacy.
The mRNA Treatment has various advantages, including vaccine preparation. mRNA is the biological preparation that induced active acquired immunity to a particular disease by stimulating the body’s immune system. Moreover, the advancement of lipid nanoparticle formulations for in vivo systemic delivery of mRNA fueling the development of in vivo transfection strategies.
The increasing prevalence of cancer, viral infections, and genetic disorders drive the mRNA treatment market. Additionally, raising awareness about vaccination fueling the global mRNA market. Furthermore, mRNA is being used to produce viral antigen proteins from within the cell are one of the promising therapies for viral disease. For instance, due to the outbreak of COVID-19 number of companies conducting clinical trials for vaccine development is projected to create lucrative opportunities in the near future. North America is dominating the market owing to the presence of key players in the region.
Competitive Landscape
Some Of The Key Players In The mRNA Treatment Market:
- CureVac,
- Moderna,
- BioNTech (Pfizer),
- Translate Bio,
- Ethris (AstraZeneca),
- Kernal Biologics,
- Anima Biotech,
- H3 Biomedicine Inc.,
- Arcturus Therapeutics,
- eFFECTOR Therapeutics, Inc.,
- Ionis Pharmaceuticals, Inc.,
- Stemirna Therapeutics Co., Ltd.,
- Skyhawk Therapeutics, Inc.,
- RNAimmune (Sirnaomics),
- Ziphius Therapeutics NV,
- miRagen Therapeutics, Inc.,
- Silence Therapeutics,
- eTheRNA,
- Tiba Biotechnology,
- In-Cell-Art,
- Arcturus Therapeutics
Market Segmentation
The Global mRNA Treatment market is segmented on the basis of product type, Therapeutic Area, Route of Administration, and region. Based on the product type, the market is divided into mRNA therapeutics and mRNA vaccines. On the basis of Therapeutic Area, the market is divided into Infectious Diseases, Oncological Disorders, Other Disorders. On the basis of Route of Administration, the market is divided into Intravenous, Intramuscular, Intranasal, and Others. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that, Europe held the largest share of the market, followed by America and the Asia Pacific. On the other hand, North America is expected to dominate the market during the analysis of the forecast period.
Recent Developments:
- In September 2023, Ethris and Heqet Therapeutics worked together to develop RNA-based cardiovascular therapeutics. Ethris granted the utilisation of its exclusive Stabilised NanoParticle (SNaP) lipid nanoparticle (LNP) platform in return for milestone and royalty payments as stipulated in this agreement. With an emphasis on remedies for heart failure and myocardial infarction, Heqet oversaw the drug development efforts.
mRNA Treatment Market Report Scope
|
Report Attribute |
Specifications |
|
Estimated Market Size Value In 2024 |
USD 8.03 Billion |
|
Revenue Forecast In 2031 |
USD 1.05 Billion |
|
Growth Rate CAGR |
CAGR of 9 % from 2028 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product Type, By Therapeutic Area, By Route of Administration |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
CureVac, Moderna, BioNTech (Pfizer), Translate Bio, Ethris (AstraZeneca), Kernal Biologics, Anima Biotech, H3 Biomedicine Inc., Arcturus Therapeutics, eFFECTOR Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Stemirna Therapeutics Co., Ltd., Skyhawk Therapeutics, Inc., RNAimmune (Sirnaomics), Ziphius Therapeutics NV, miRagen Therapeutics, Inc., Silence Therapeutics, eTheRNA, Tiba Biotechnology, In-Cell-Art, Arcturus Therapeutics among others. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
